SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space.

盐湖城，2023年11月9日（GLOBE NEWSWIRE）-递归（纳斯达克股票代码：RXRX），一家领先的临床阶段TechBio公司解码生物学以实现药物发现工业化，今天宣布与其合作者NVIDIA和拜耳进行两次重大更新，以及与Tempus Labs的新合作，因为它创建了基础设施并扩大了其在精确肿瘤学领域的雄心壮志和范围。

“Since our founding we have believed that the next generation of biopharma leaders would operate at the intersection of scaled datasets and accelerated computing,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “Today, we are thrilled to share three major initiatives that support this belief and our mission to bring better medicines to patients at speed and scale.

“自从我们成立以来，我们相信下一代生物制药领导者将在规模数据集和加速计算的交叉点上运作，”递归联合创始人兼首席执行官克里斯·吉布森博士说。“今天，我们很高兴分享三项主要举措，支持这一信念和我们的使命，即快速，大规模地为患者带来更好的药物。

With Tempus’s 20 petabytes of fit-for-purpose precision oncology data, NVIDIA’s support in quadrupling our supercomputing power to rapidly and reliably advance the exploration and construction of large AI models, and updating our collaboration with Bayer to rapidly pursue a set of precision oncology programs, we will continue to drive the transformation from BioTech to TechBio together.” Tempus Collaboration Provides Recursion with Access to Data Containing More Than 20 Petabytes of Proprietary Patient-Centric Oncology Data Recursion has come to an agreement with Tempus for preferred access to one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models.

凭借Tempus 20 PB的专用精确肿瘤学数据，NVIDIA支持将我们的超级计算能力提高四倍，以快速可靠地推进大型AI模型的探索和构建，并更新我们与拜耳的合作，以快速追求一套精确的肿瘤学计划，我们将继续推动从生物技术到TechBio的转型。”Tempus协作提供对包含超过20 PB专有以患者为中心的肿瘤学数据的数据的访问的递归与Tempus达成协议，以便优先访问世界上最大的专有，未识别，以患者为中心的肿瘤学数据集之一，跨越DNA，RNA，健康记录和更多支持通过训练因果AI模型大规模发现潜在的富含生物标志物的治疗方法。

By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, the company believes it has an opportunity to improve the speed, precisi.

通过将Tempus的前向遗传学方法与递归的反向遗传学方法相结合，公司认为它有机会提高速度，精确度。